JS
Therapeutic Areas
Vistagen Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Fasedienol (PH94B) | Social Anxiety Disorder | Phase 3 |
| Itruvone (PH10) | Major Depressive Disorder | Phase 2 |
| PH80 | Prevention of Migraine | Preclinical |
Leadership Team at Vistagen Therapeutics
SK
Shawn K. Singh
Chief Executive Officer, Director
RG
Reid G. Adler
Chief Corporate Development Officer
C(
Cynthia (Cindi) V. Anderson
Chief Financial Officer
MR
Michael R. (Mick) O'Donnell
Senior Vice President, Discovery Research
R(
Robert (Bobby) W. Azelby
Chairman of the Board